{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:27:53Z","timestamp":1790832473535,"version":"4.1.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple Myeloma (MM), the second most common hematologic malignancy, has been the target of many therapeutic advances over the past two decades. The introduction of novel agents, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, along with autologous hematopoietic stem cell transplantation (ASCT) in the current standard of care, has increased the median survival of myeloma patients significantly. Nevertheless, a curative treatment option continues to elude us, and MM remains an incurable disease, with patients relapsing even after achieving deep conventionally defined responses, underscoring the need for the development of sensitive methods that will allow for proper identification and management of the patients with a higher probability of relapse. Accurate detection of Minimal Residual Disease (MRD) from a bone marrow biopsy represents a relatively new approach of evaluating response to treatment with data showing clear benefit from obtaining MRD(-) status at any point of the disease course. As life expectancy for patients with MM continues to increase and deep responses are starting to become the norm, establishing and refining the role of MRD in the disease course is more relevant than ever. This review examines the different methods used to detect MRD and discusses future considerations regarding the implementation in day-to-day clinical practice and as a prospective primary endpoint for clinical trials.<\/jats:p>","DOI":"10.3389\/fonc.2021.801851","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T05:01:56Z","timestamp":1643173316000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications"],"prefix":"10.3389","volume":"11","author":[{"given":"Charalampos","family":"Charalampous","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab Plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0271-1","article-title":"Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse","volume":"33","author":"Sidana","year":"2019","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11534","article-title":"Complete Response Correlates With Long-Term Survival and Progression-Free Survival in High-Dose Therapy in Multiple Myeloma","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422683","article-title":"A Phase 1\/2 Study of Carfilzomib in Combination With Lenalidomide and Low-Dose Dexamethasone as a Frontline Treatment for Multiple Myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall Survival With Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-Label, Phase 3 Trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.435.435","article-title":"Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal Residual Disease Negativity Using Deep Sequencing is a Major Prognostic Factor in Multiple Myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112790","article-title":"Efficacy of Maintenance Therapy Following Auto-HSCT Depending on MRD Status in Patients With Multiple Myeloma","volume":"132","author":"Solovev","year":"2018","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-573733","article-title":"GEM2005 Trial Update Comparing VMP\/VTP as Induction in Elderly Multiple Myeloma Patients: Do We Still Need Alkylators","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow Antibody Panels for Standardized N-Dimensional Flow Cytometric Immunophenotyping of Normal, Reactive and Malignant Leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.191.191","article-title":"Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM\/DFCI 2009 Trial","volume":"126","author":"Avet-Loiseau","year":"2015","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD Detection in Multiple Myeloma: Comparison Between MSKCC 10-Color Single-Tube and EuroFlow 8-Color 2-Tube Methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01231","article-title":"Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25641","article-title":"Stability and Uniqueness of Clonal Immunoglobulin CDR3 Sequences for MRD Tracking in Multiple Myeloma","volume":"94","author":"Rustad","year":"2019","journal-title":"Am J Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.02.007","article-title":"Minimal Residual Disease Detection of Myeloma Using Sequencing of Immunoglobulin Heavy Chain Gene VDJ Regions","volume":"55","author":"Ho","year":"2018","journal-title":"Semin Hematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical Evaluation of the clonoSEQ Assay for Establishing Measurable (Minimal) Residual Disease in Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05120.x","article-title":"Post-Transplantation Tumour Load in Bone Marrow, as Assessed by Quantitative ASO-PCR, Is a Prognostic Parameter in Multiple Myeloma","volume":"126","author":"Bakkus","year":"2004","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.375","article-title":"Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease Detection in B-Cell Disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.217","article-title":"Critical Evaluation of ASO RQ-PCR for Minimal Residual Disease Evaluation in Multiple Myeloma. A Comparative Analysis With Flow Cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6100091","article-title":"Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients With Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation","volume":"6","author":"Takamatsu","year":"2017","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124645","article-title":"Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients","volume":"134","author":"Oliva","year":"2019","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic Value of Deep Sequencing Method for Minimal Residual Disease Detection in Multiple Myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of Next-Generation Sequencing (NGS) and Next-Generation Flow (NGF) for Minimal Residual Disease (MRD) Assessment in Multiple Myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01339-6","article-title":"Liquid Biopsy: An Evolving Paradigm for the Biological Characterisation of Plasma Cell Disorders","volume":"35","author":"Mithraprabhu","year":"2021","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002610","article-title":"Blood Monitoring of Circulating Tumor Plasma Cells by Next Generation Flow in Multiple Myeloma After Therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.161414","article-title":"Monitoring Multiple Myeloma by Next-Generation Sequencing of V(D)J Rearrangements From Circulating Myeloma Cells and Cell-Free Myeloma DNA","volume":"102","author":"Oberle","year":"2017","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of Clonal Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Implications for Redefining High-Risk Myeloma","volume":"28","author":"Gonsalves","year":"2014","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0181447","DOI":"10.1371\/journal.pone.0181447","article-title":"Prognostic Value of Circulating Plasma Cells in Patients With Multiple Myeloma: A Meta-Analysis","volume":"12","author":"Li","year":"2017","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.166629","article-title":"Serial Measurements of Circulating Plasma Cells Before and After Induction Therapy Have an Independent Prognostic Impact in Patients With Multiple Myeloma Undergoing Upfront Autologous Transplantation","volume":"102","author":"Rajshekhar","year":"2017","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04428.x","article-title":"Bone Marrow Angiogenesis and Circulating Plasma Cells in Multiple Myeloma","volume":"122","author":"Kumar","year":"2003","journal-title":"Br J Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510453","article-title":"Detailed Characterization of Multiple Myeloma Circulating Tumor Cells Shows Unique Phenotypic, Cytogenetic, Functional, and Circadian Distribution Profile","volume":"122","author":"Paiva","year":"2013","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by Deep Sequencing From Circulating Tumor DNA Does Not Correlate With Results Obtained in the Bone Marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s42003-020-01515-x","article-title":"Personalized Immunoglobulin Aptamers for Detection of Multiple Myeloma Minimal Residual Disease in Serum","volume":"3","author":"Tapia-Alveal","year":"2020","journal-title":"Commun Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1021\/pr400985k","article-title":"Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients With a Monoclonal Gammopathy","volume":"13","author":"Barnidge","year":"2014","journal-title":"J Proteome Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e590","DOI":"10.1038\/bcj.2017.75","article-title":"High Sensitivity Blood-Based M-Protein Detection in sCR Patients With Multiple Myeloma","volume":"7","author":"Mills","year":"2017","journal-title":"Blood Cancer J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4254","article-title":"Comparison of Mass Spectrometry and Flow Cytometry in Measuring Minimal Residual Disease in Multiple Myeloma","volume":"10","author":"Foureau","year":"2021","journal-title":"Cancer Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24772","article-title":"The Utility of MASS-FIX to Detect and Monitor Monoclonal Proteins in the Clinic","volume":"92","author":"Milani","year":"2017","journal-title":"Am J Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16443","article-title":"Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow-Based Flow Cytometry for Tracking Measurable Residual Disease in Patients With Multiple Myeloma","volume":"189","author":"Eveillard","year":"2020","journal-title":"Br J Haematol"},{"key":"B44","volume-title":"820 Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment","author":"Giles","year":"2021"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051248","article-title":"The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma","volume":"20","author":"Rasche","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [(18)F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM Study","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-Fluorodeoxyglucose Positron Emission Tomography in the Context of Other Imaging Techniques and Prognostic Factors in Multiple Myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e318266cee2","article-title":"The Value of 18F-FDG PET\/CT After Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients","volume":"38","author":"Nanni","year":"2013","journal-title":"Clin Nucl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to Suppression of Focal Lesions on Positron Emission Tomography-Computed Tomography Is a Therapeutic Goal in Newly Diagnosed Multiple Myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123143","article-title":"Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-Up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25507","article-title":"Imaging and Bone Marrow Assessments Improve Minimal Residual Disease Prediction in Multiple Myeloma","volume":"94","author":"Alonso","year":"2019","journal-title":"Am J Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18F-FDG\u2013PET\/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-018-0738-z","article-title":"Diagnostic Performance of (18)F-FDG PET\/CT and Whole-Body MRI Before and Early After Treatment of Multiple Myeloma: A Prospective Comparative Study","volume":"36","author":"Basha","year":"2018","journal-title":"Jpn J Radiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-012-2600-5","article-title":"Comparative Diagnostic Performance of \u00b9\u2078F-FDG PET\/CT Versus Whole-Body MRI for Determination of Remission Status in Multiple Myeloma After Stem Cell Transplantation","volume":"23","author":"Derlin","year":"2013","journal-title":"Eur Radiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2012.06.028","article-title":"Contrast Enhanced MRI and \u00b9\u2078F-FDG PET-CT in the Assessment of Multiple Myeloma: A Comparison of Results in Different Phases of the Disease","volume":"81","author":"Spinnato","year":"2012","journal-title":"Eur J Radiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.18.20989","article-title":"Comparison of Whole-Body DWI and (18)F-FDG PET\/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma","volume":"213","author":"Chen","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04265-2","article-title":"Prospective Comparison of 18-FDG PET\/CT and Whole-Body Diffusion-Weighted MRI in the Assessment of Multiple Myeloma","volume":"99","author":"Mesguich","year":"2020","journal-title":"Ann Hematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low Expression of Hexokinase-2 Is Associated With False-Negative FDG\u2013positron Emission Tomography in Multiple Myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.217539","article-title":"Hexokinase-2 Expression in (11)C-Methionine-Positive, (18)F-FDG-Negative Multiple Myeloma","volume":"60","author":"Kircher","year":"2019","journal-title":"J Nucl Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.338","article-title":"Whole-Body Diffusion-Weighted MRI: A New Gold Standard for Assessing Disease Burden in Patients With Multiple Myeloma","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.3390\/jcm9113519","article-title":"Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients","volume":"9","author":"Zamagni","year":"2020","journal-title":"J Clin Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD Profiling Defines Outcome and Unveils Different Modes of Treatment Resistance in Standard- and High-Risk Myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA\/GEM Clinical Trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03609-x","article-title":"Achieving Minimal Residual Disease-Negative by Multiparameter Flow Cytometry may Ameliorate a Poor Prognosis in MM Patients With High-Risk Cytogenetics: A Retrospective Single-Center Analysis","volume":"98","author":"Li","year":"2019","journal-title":"Ann Hematol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.bbmt.2017.01.076","article-title":"Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma With High-Risk Cytogenetics","volume":"23","author":"Chakraborty","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31854","article-title":"Minimal Residual Disease by Flow Cytometry and Allelic-Specific Oligonucleotide Real-Time Quantitative Polymerase Chain Reaction in Patients With Myeloma Receiving Lenalidomide Maintenance: A Pooled Analysis","volume":"125","author":"Gambella","year":"2019","journal-title":"Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165217","article-title":"The Prognostic Value of the Depth of Response in Multiple Myeloma Depends on the Time of Assessment, Risk Status and Molecular Subtype","volume":"102","author":"Schinke","year":"2017","journal-title":"Haematologica"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.1864.1864","article-title":"Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients With Deferred ASCT (PADIMAC)","volume":"130","author":"Popat","year":"2017","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1121262","article-title":"Prognostic Impact of Immunophenotypic Complete Response in Patients With Multiple Myeloma Achieving Better Than Complete Response","volume":"57","author":"Fukumoto","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.774","article-title":"BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations From the Organizing Committee","volume":"24","author":"Holstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter Flow Cytometric Remission is the Most Relevant Prognostic Factor for Multiple Myeloma Patients Who Undergo Autologous Stem Cell Transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.040","article-title":"Longitudinal Flow Cytometry Identified \"Minimal Residual Disease\" (MRD) Evolution Patterns for Predicting the Prognosis of Patients With Transplant-Eligible Multiple Myeloma","volume":"24","author":"Gu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B75","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/cyto.b.21755","article-title":"Minimal Residual Disease and Log-Reduction of Plasma Cells Are Associated With Superior Response After Double Autologous Stem Cell Transplant in Younger Patients With Multiple Myeloma","volume":"96","author":"Rossi","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.58","article-title":"Analytical and Clinical Validation of a Novel in-House Deep-Sequencing Method for Minimal Residual Disease Monitoring in a Phase II Trial for Multiple Myeloma","volume":"31","author":"Martinez-Lopez","year":"2017","journal-title":"Leukemia"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients With Multiple Myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116426","article-title":"Maintenance With Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease","volume":"132","author":"Yong","year":"2018","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115162","article-title":"The Prognostic Value of Multiparameter Flow Cytometry Minimal Residual Disease Assessment in Relapsed Multiple Myeloma","volume":"100","author":"Paiva","year":"2015","journal-title":"Haematologica"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113177","article-title":"Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed\/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated With Daratumumab in Combination With Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor","volume":"132","author":"Avet-Loiseau","year":"2018","journal-title":"Blood"},{"key":"B82","volume-title":"82 Daratumumab (DARA) With Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2","author":"Avet-Loiseau","year":"2021"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International Harmonization in Performing and Reporting Minimal Residual Disease Assessment in Multiple Myeloma Trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of Minimal Residual Disease in Patients With Multiple Myeloma on Continuous Lenalidomide Maintenance: A Single-Arm, Single-Centre, Phase 2 Trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous Transplantation and Maintenance Therapy in Multiple Myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy Plus Lenalidomide Versus Autologous Transplantation, Followed by Lenalidomide Plus Prednisone Versus Lenalidomide Maintenance, in Patients With Multiple Myeloma: A Randomised, Multicentre, Phase 3 Trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of Carfilzomib Lenalidomide Dexamethasone (KRd) With or Without Transplantation in Newly Diagnosed Myeloma According to Risk Status: Results From the FORTE Trial","volume":"37","author":"Gay","year":"2019","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123170","article-title":"Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients With Newly Diagnosed Multiple Myeloma (NDMM)","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126378","article-title":"Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study","volume":"134","author":"Landgren","year":"2019","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.801851\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T05:02:01Z","timestamp":1643173321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.801851\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":91,"alternative-id":["10.3389\/fonc.2021.801851"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.801851","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"article-number":"801851"}}